BioSpace News Archive

Bonus BioGroup’s product is back in the news again as its cell therapy promises to treat late-stage COVID-19.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS).

Neovasc Inc. announced that the United Kingdom’s Interventional Procedures Programme at the National Institute for Health and Care Excellence has issued guidance supporting the implantation of the Neovasc Reducer™ in appropriate patients suffering from refractory angina, a painful and debilitating condition that causes chest pain when other treatment options have failed or are not possible.

Health Canada has completed its onsite inspection of the Emergent BioSolutions facility in Baltimore, Maryland . The European Medicines Agency and South African Health Products Regulatory Authority also participated in this inspection remotely.

An experimental compound reduced complications of type 1 and type 2 diabetes in mice – not by lowering blood sugar – but by countering its consequences: cell death, inflammation, and organ damage.

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the fourth annual Evercore ISI HealthCONx Conference on Thursday, Dec. 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).

Zynex, Inc. (NASDAQ: ZYXI), today announced the company will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced financial results for the third quarter ended September 30, 2021.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 76,000 shares of the Company’s common stock at an exercise price per share of $48.47, which was the closing price on November 23, 2021.